Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Biomolecules 2012, 2(4), 435-466; doi:10.3390/biom2040435
Review

Sialyl-Tn in Cancer: (How) Did We Miss the Target?

1,* , 2
 and 1
Received: 29 August 2012; in revised form: 27 September 2012 / Accepted: 30 September 2012 / Published: 11 October 2012
(This article belongs to the Special Issue Challenges in Glycan, Glycoprotein and Proteoglycan Research)
View Full-Text   |   Download PDF [853 KB, uploaded 11 October 2012]   |   Browse Figures
Abstract: Sialyl-Tn antigen (STn) is a short O-glycan containing a sialic acid residue a2,6-linked to GalNAca-O-Ser/Thr. The biosynthesis of STn is mediated by a specific sialyltransferase termed ST6GalNAc I, which competes with O-glycans elongating glycosyltransferases and prevents cancer cells from exhibiting longer O-glycans. While weakly expressed by fetal and normal adult tissues, STn is expressed by more than 80% of human carcinomas and in all cases, STn detection is associated with adverse outcome and decreased overall survival for the patients. Because of its pan-carcinoma expression associated with an adverse outcome, an anti-cancer vaccine, named Theratope, has been designed towards the STn epitope. In spite of the great enthusiasm around this immunotherapy, Theratope failed on Phase III clinical trial. However, in lieu of missing this target, one should consider to revise the Theratope design and the actual facts. In this review, we highlight the many lessons that can be learned from this failure from the immunological standpoint, as well as from the drug design and formulation and patient selection. Moreover, an irrefutable knowledge is arising from novel immunotherapies targeting other carbohydrate antigens and STn carrier proteins, such as MUC1, that will warrantee the future development of more successful anti-STn immunotherapy strategies.
Keywords: Sialyl-Tn antigen; O-glycan; ST6GalNAc I; Theratope; cancer immunotherapy Sialyl-Tn antigen; O-glycan; ST6GalNAc I; Theratope; cancer immunotherapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Julien, S.; Videira, P.A.; Delannoy, P. Sialyl-Tn in Cancer: (How) Did We Miss the Target? Biomolecules 2012, 2, 435-466.

AMA Style

Julien S, Videira PA, Delannoy P. Sialyl-Tn in Cancer: (How) Did We Miss the Target? Biomolecules. 2012; 2(4):435-466.

Chicago/Turabian Style

Julien, Sylvain; Videira, Paula A.; Delannoy, Philippe. 2012. "Sialyl-Tn in Cancer: (How) Did We Miss the Target?" Biomolecules 2, no. 4: 435-466.



Biomolecules EISSN 2218-273X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert